Quantitative Structure Activity/pharmacokinetics Relationship Studies of HIV-1 Protease Inhibitors Using Three Modelling Methods

摘要

Background: HIV-1 protease inhibitor (PIs) is a good choice for AIDS patients. Nevertheless, for PIs, there are several bugs in clinical application, like drug resistance, the large dose, the high costs and so on, among which, the poor pharmacokinetics property is one of the important reasons that leads to the failure of its clinical application.